Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

NCT06757634 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1180

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Arm A: Gedatolisib + Palbociclib + Fulvestrant
DRUG: Arm B: Ribociclib + Fulvestrant
DRUG: Arm C: Gedatolisib + Palbociclib + Letrozole
DRUG: Arm D: Ribociclib + Letrozole

Sponsor

Celcuity Inc